Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice Postic C; Girard JJ Clin Invest 2008[Mar]; 118 (3): 829-38Nonalcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance, and type 2 diabetes. NAFLD represents a large spectrum of diseases ranging from (i) fatty liver (hepatic steatosis); (ii) steatosis with inflammation and necrosis; and (iii) cirrhosis. Although the molecular mechanism leading to the development of hepatic steatosis in the pathogenesis of NAFLD is complex, recent animal models have shown that modulating important enzymes in fatty acid synthesis in liver may be key for the treatment of NAFLD. This review discusses recent advances in the field.|*Insulin Resistance[MESH]|Acetyl-CoA Carboxylase/antagonists & inhibitors[MESH]|Acetyltransferases/antagonists & inhibitors[MESH]|Animals[MESH]|Basic Helix-Loop-Helix Leucine Zipper Transcription Factors[MESH]|Fatty Acid Synthases/physiology[MESH]|Fatty Acids/*biosynthesis[MESH]|Fatty Liver/*etiology/metabolism/prevention & control[MESH]|Humans[MESH]|Lipoproteins, VLDL/biosynthesis[MESH]|Liver/*metabolism[MESH]|Mice[MESH]|Mice, Transgenic[MESH]|Nuclear Proteins/physiology[MESH]|Stearoyl-CoA Desaturase/deficiency[MESH]|Transcription Factors/physiology[MESH]|Triglycerides/biosynthesis[MESH] |
